% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Vogelgsang:271866,
author = {Vogelgsang, Jonathan and Hansen, Niels and Stark, Melina
and Wagner, Michael and Klafki, Hans and Morgado, Barbara
Marcos and Jahn-Brodmann, Anke and Schott, Björn and
Esselmann, Hermann and Bauer, Chris and Schuchhardt,
Johannes and Kleineidam, Luca and Wolfsgruber, Steffen and
Peters, Oliver and Schneider, Luisa-Sophie and Wang, Xiao
and Menne, Felix and Priller, Josef and Spruth, Eike Jakob
and Altenstein, Slawek and Lohse, Andrea and Schneider, Anja
and Fliessbach, Klaus and Vogt, Ina and Bartels, Claudia and
Jessen, Frank and Rostamzadeh, Ayda and Duezel, Emrah and
Glanz, Wenzel and Incesoy, Enise and Butryn, Michaela and
Buerger, Katharina and Janowitz, Daniel and Ewers, Michael
and Perneczky, Robert and Rauchmann, Boris Stephan and
Guersel, Selim and Teipel, Stefan and Kilimann, Ingo and
Goerss, Doreen and Laske, Christoph and Munk, Matthias and
Sanzenbacher, Carolin and Spottke, Annika and Roy-Kluth,
Nina and Heneka, Michael and Brosseron, Frederic and
Ramirez, Alfredo and Schmid, Matthias and Wiltfang, Jens},
title = {{P}lasma amyloid beta {X}-42/{X}-40 ratio and cognitive
decline in suspected early and preclinical {A}lzheimer's
disease.},
journal = {Alzheimer's and dementia},
volume = {20},
number = {8},
issn = {1552-5260},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {DZNE-2024-01078},
pages = {5132 - 5142},
year = {2024},
abstract = {Blood-based biomarkers are a cost-effective and minimally
invasive method for diagnosing the early and preclinical
stages of amyloid positivity (AP). Our study aims to
investigate our novel immunoprecipitation-immunoassay
(IP-IA) as a test for predicting cognitive decline.We
measured levels of amyloid beta (Aβ)X-40 and AβX-42 in
immunoprecipitated eluates from the DELCODE cohort.
Receiver-operating characteristic (ROC) curves, regression
analyses, and Cox proportional hazard regression models were
constructed to predict AP by Aβ42/40 classification in
cerebrospinal fluid (CSF) and conversion to mild cognitive
impairment (MCI) or dementia.We detected a significant
correlation between AßX-42/X-40 in plasma and CSF (r =
0.473). Mixed-modeling analysis revealed a substantial
prediction of AßX-42/X-40 with an area under the curve
(AUC) of 0.81 for AP (sensitivity: 0.79, specificity: 0.74,
positive predictive value [PPV]: 0.71, negative predictive
value [NPV]: 0.81). In addition, lower AβX-42/X-40 ratios
were associated with negative PACC5 slopes, suggesting
cognitive decline.Our results suggest that assessing the
plasma AβX-42/X-40 ratio via our semiautomated IP-IA is a
promising biomarker when examining patients with early or
preclinical AD.New plasma Aβ42/Aβ40 measurement using
immunoprecipitation-immunoassay Plasma Aβ42/Aβ40
associated with longitudinal cognitive decline Promising
biomarker to detect subjective cognitive decline at-risk for
brain amyloid positivity.},
keywords = {Humans / Amyloid beta-Peptides: blood / Amyloid
beta-Peptides: cerebrospinal fluid / Alzheimer Disease:
blood / Alzheimer Disease: diagnosis / Alzheimer Disease:
cerebrospinal fluid / Cognitive Dysfunction: blood /
Cognitive Dysfunction: cerebrospinal fluid / Cognitive
Dysfunction: diagnosis / Male / Female / Aged / Biomarkers:
blood / Biomarkers: cerebrospinal fluid / Peptide Fragments:
blood / Peptide Fragments: cerebrospinal fluid / Middle Aged
/ ROC Curve / Immunoprecipitation / Disease Progression /
Alzheimer's disease (Other) / MCI (Other) / amyloid beta
(Other) / biomarker (Other) / dementia (Other) / plasma
(Other) / Amyloid beta-Peptides (NLM Chemicals) / Biomarkers
(NLM Chemicals) / Peptide Fragments (NLM Chemicals) /
amyloid beta-protein (1-42) (NLM Chemicals) / amyloid
beta-protein (1-40) (NLM Chemicals)},
cin = {AG Wiltfang / AG Wagner / AG Peters / AG Priller / AG
Schneider / Patient Studies (Bonn) / AG Spottke / AG Jessen
/ AG Düzel / Clinical Research (Munich) / AG Dichgans / AG
Teipel / AG Gasser / AG Heneka / AG Schmid Bonn},
ddc = {610},
cid = {I:(DE-2719)1410006 / I:(DE-2719)1011201 /
I:(DE-2719)5000000 / I:(DE-2719)5000007 / I:(DE-2719)1011305
/ I:(DE-2719)1011101 / I:(DE-2719)1011103 /
I:(DE-2719)1011102 / I:(DE-2719)5000006 / I:(DE-2719)1111015
/ I:(DE-2719)5000022 / I:(DE-2719)1510100 /
I:(DE-2719)1210000 / I:(DE-2719)1011303 /
I:(DE-2719)1013028},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pmc = {pmc:PMC11350048},
pubmed = {pmid:38940303},
doi = {10.1002/alz.13909},
url = {https://pub.dzne.de/record/271866},
}